Grants and Contributions:
Title:
UK BioM- 10138929 - EXHEPA_TARG_HAGL_GBP - Extrahepatic Targeting of Therapeutic Payloads Via High Affinity Glycan Ligands and Glycan Binding Proteins
Agreement Number:
1029473
Agreement Value:
$899,670.00
Agreement Date:
Apr 1, 2025 - Mar 30, 2027
Description:
This project will develop an innovative platform for delivering mRNA therapies with enhanced precision to specific cells. It moves beyond traditional delivery methods by incorporating glycan-based targeting ligands, which offer a new active targeting approach. This strategy has broad therapeutic applications, with the potential to greatly improve treatment outcomes.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Ottawa, Ontario, CA K1A 0R6
Reference Number:
172-2025-2026-Q1-1029473
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
897184792
Recipient Type:
For-profit organization
Recipient's Legal Name:
Sussex Research Laboratories Inc.
Federal Riding Name:
Ottawa--Vanier
Federal Riding Number:
35078
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710